These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 33052954)
1. Tolerability of oral itraconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A systematic review and meta-analysis. Olum R; Baluku JB; Kazibwe A; Russell L; Bongomin F PLoS One; 2020; 15(10):e0240374. PubMed ID: 33052954 [TBL] [Abstract][Full Text] [Related]
2. Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events. Bongomin F; Maguire N; Moore CB; Felton T; Rautemaa-Richardson R Mycoses; 2019 Mar; 62(3):217-222. PubMed ID: 30570179 [TBL] [Abstract][Full Text] [Related]
3. Anti-fungal agents in the treatment of chronic pulmonary aspergillosis: Systematic review and a network meta-analysis. Sehgal IS; Dhooria S; Prasad KT; Muthu V; Aggarwal AN; Chakrabarti A; Agarwal R Mycoses; 2021 Sep; 64(9):1053-1061. PubMed ID: 34031920 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan. Saito T; Fujiuchi S; Tao Y; Sasaki Y; Ogawa K; Suzuki K; Tada A; Kuba M; Kato T; Kawabata M; Kurashima A; Sakatani M; Infection; 2012 Dec; 40(6):661-7. PubMed ID: 22956473 [TBL] [Abstract][Full Text] [Related]
6. [An open, noncomparative multicenter study of the efficacy and safety of itraconazole injections and high dose capsules in chronic pulmonary aspergillosis]. Tomioka H; Kaneda T; Kida Y; Kaneko M; Fujii H; Hayashi M; Tomii K; Tada K; Suzuki Y; Karino T Kansenshogaku Zasshi; 2011 Nov; 85(6):644-51. PubMed ID: 22250455 [TBL] [Abstract][Full Text] [Related]
7. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Sambatakou H; Dupont B; Lode H; Denning DW Am J Med; 2006 Jun; 119(6):527.e17-24. PubMed ID: 16750972 [TBL] [Abstract][Full Text] [Related]
8. Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature. Agarwal R; Vishwanath G; Aggarwal AN; Garg M; Gupta D; Chakrabarti A Mycoses; 2013 Sep; 56(5):559-70. PubMed ID: 23496375 [TBL] [Abstract][Full Text] [Related]
10. Selection of Oral Antifungals for Initial Maintenance Therapy in Chronic Pulmonary Aspergillosis: A Longitudinal Analysis. Tashiro M; Takazono T; Saijo T; Yamamoto K; Imamura Y; Miyazaki T; Kakeya H; Ando T; Ogawa K; Kishi K; Tokimatsu I; Hayashi Y; Fujiuchi S; Yanagihara K; Miyazaki Y; Ichihara K; Mukae H; Kohno S; Izumikawa K Clin Infect Dis; 2020 Feb; 70(5):835-842. PubMed ID: 30959519 [TBL] [Abstract][Full Text] [Related]
11. Treatment of chronic pulmonary aspergillosis with voriconazole: review of a case series. Cucchetto G; Cazzadori A; Conti M; Cascio GL; Braggio P; Concia E Infection; 2015 Jun; 43(3):277-86. PubMed ID: 25432571 [TBL] [Abstract][Full Text] [Related]
12. High detection rate of azole-resistant Aspergillus fumigatus after treatment with azole antifungal drugs among patients with chronic pulmonary aspergillosis in a single hospital setting with low azole resistance. Takeda K; Suzuki J; Watanabe A; Arai T; Koiwa T; Shinfuku K; Narumoto O; Kawashima M; Fukami T; Tamura A; Nagai H; Matsui H; Kamei K Med Mycol; 2021 Apr; 59(4):327-334. PubMed ID: 32642756 [TBL] [Abstract][Full Text] [Related]
13. Antifungals in a case of basidiobolomycosis: role and limitations. Saeed A; Assiri AM; Bukhari IA; Assiri R BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31570348 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of 12-months oral itraconazole versus 6-months oral itraconazole to prevent relapses of chronic pulmonary aspergillosis: an open-label, randomised controlled trial in India. Sehgal IS; Dhooria S; Muthu V; Prasad KT; Aggarwal AN; Chakrabarti A; Choudhary H; Garg M; Agarwal R Lancet Infect Dis; 2022 Jul; 22(7):1052-1061. PubMed ID: 35429465 [TBL] [Abstract][Full Text] [Related]
15. Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial. Cadranel J; Philippe B; Hennequin C; Bergeron A; Bergot E; Bourdin A; Cottin V; Jeanfaivre T; Godet C; Pineau M; Germaud P Eur J Clin Microbiol Infect Dis; 2012 Nov; 31(11):3231-9. PubMed ID: 22782438 [TBL] [Abstract][Full Text] [Related]
16. An overview of the available treatments for chronic cavitary pulmonary aspergillosis. Sehgal IS; Dhooria S; Muthu V; Prasad KT; Agarwal R Expert Rev Respir Med; 2020 Jul; 14(7):715-727. PubMed ID: 32249630 [TBL] [Abstract][Full Text] [Related]
17. An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis. Queiroz-Telles F; Goldani LZ; Schlamm HT; Goodrich JM; Espinel-Ingroff A; Shikanai-Yasuda MA Clin Infect Dis; 2007 Dec; 45(11):1462-9. PubMed ID: 17990229 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Mattiuzzi GN; Cortes J; Alvarado G; Verstovsek S; Koller C; Pierce S; Blamble D; Faderl S; Xiao L; Hernandez M; Kantarjian H Support Care Cancer; 2011 Jan; 19(1):19-26. PubMed ID: 19956980 [TBL] [Abstract][Full Text] [Related]
19. Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. Chishimba L; Niven RM; Cooley J; Denning DW J Asthma; 2012 May; 49(4):423-33. PubMed ID: 22380765 [TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of sequential therapy with voriconazole on COPD patients in acute phase with pulmonary aspergillosis and effects on cytokines and pulmonary functions. Du JF; Chi YM; Song Z; Di QG; Shi J; Lv J; Mai ZT; Li M; Sun BH; Jiang MM Eur Rev Med Pharmacol Sci; 2018 Mar; 22(6):1837-1842. PubMed ID: 29630134 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]